167 related articles for article (PubMed ID: 35332886)
21. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers in prostate cancer management. Is there something new?
Carrion DM; Gómez Rivas J; Álvarez-Maestro M; Martínez-Piñeiro L
Arch Esp Urol; 2019 Mar; 72(2):105-115. PubMed ID: 30855011
[TBL] [Abstract][Full Text] [Related]
23. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
[TBL] [Abstract][Full Text] [Related]
24. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
Clark JP; Munson KW; Gu JW; Lamparska-Kupsik K; Chan KG; Yoshida JS; Kawachi MH; Crocitto LE; Wilson TG; Feng Z; Smith SS
Clin Chem; 2008 Dec; 54(12):2007-17. PubMed ID: 18948370
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
26. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.
Loeb S; Bruinsma SM; Nicholson J; Briganti A; Pickles T; Kakehi Y; Carlsson SV; Roobol MJ
Eur Urol; 2015 Apr; 67(4):619-26. PubMed ID: 25457014
[TBL] [Abstract][Full Text] [Related]
27. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
28. The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.
Hernandez J; Gelfond J; Goros M; Liss MA; Liang Y; Ankerst D; Thompson IM; Leach RJ
PLoS One; 2018; 13(10):e0204823. PubMed ID: 30300367
[TBL] [Abstract][Full Text] [Related]
29. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.
Yang Z; Yu L; Wang Z
Chin J Cancer Res; 2016 Feb; 28(1):65-71. PubMed ID: 27041928
[TBL] [Abstract][Full Text] [Related]
30. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers of Aggressive Prostate Cancer at Diagnosis.
Boehm BE; York ME; Petrovics G; Kohaar I; Chesnut GT
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768533
[TBL] [Abstract][Full Text] [Related]
32. Urinary biomarkers of prostate cancer.
Fujita K; Nonomura N
Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
[TBL] [Abstract][Full Text] [Related]
33. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
[TBL] [Abstract][Full Text] [Related]
34. Novel Biomarkers for Prostate Cancer Detection and Prognosis.
Filella X; Foj L
Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547
[TBL] [Abstract][Full Text] [Related]
35. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
[TBL] [Abstract][Full Text] [Related]
36. PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer.
Warli SM; Warli MH; Prapiska FF
Res Rep Urol; 2023; 15():149-155. PubMed ID: 37181497
[TBL] [Abstract][Full Text] [Related]
37. The novel prostate cancer antigen 3 (PCA3) biomarker.
Bourdoumis A; Papatsoris AG; Chrisofos M; Efstathiou E; Skolarikos A; Deliveliotis C
Int Braz J Urol; 2010; 36(6):665-8; discussion 669. PubMed ID: 21176272
[TBL] [Abstract][Full Text] [Related]
38. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
Bernardeau S; Charles T; Fromont-Hankard G; Irani J
Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer: Urinary PCA3 and TMPRSS2:ERG reduce the need for repeat biopsy.
Sidaway P
Nat Rev Urol; 2015 Oct; 12(10):536. PubMed ID: 26345208
[No Abstract] [Full Text] [Related]
40. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
